Arovella Therapeutics releases second ALA-101 clinical batch for immediate patient use
Arovella Therapeutics (ASX: ALA) has manufactured and released a second clinical batch of ALA-101, which the company says is ready for immediate patient use. The company stated the batch proves the “reproducibility and scalability” of its manufacturing process.
The two batches released so far provide sufficient material to complete dose escalation and begin dose expansion in blood cancers. First patient dosing is expected this month, with dosing expected in late October.
For investors, the announcement shifts the focus from manufacturing to trial execution, with clinical material and hospital sites now in place.
Key highlights from the announcement:
- Two batches of ALA-101 have been released so far
- A third batch is expected to be released by end December
- The phase 1 trial is planned for 46 patients over five hospital sites
- A site at Epworth Hospital has been activated
- St Vincent’s Hospital (Sydney) and Mater Hospital (Brisbane) are expected to be activated soon
When big ASX news breaks, our subscribers know first
How off-the-shelf manufacturing addresses the CAR-T bottleneck
What is CAR-T and why manufacturing matters
CAR-T therapies use immune cells modified with a Chimeric Antigen Receptor (CAR) to target cancer cells. According to the company, manufacturing is a bottleneck for conventional autologous CAR-T therapies, which require product to be made using each patient’s own cells.
That complex and individualised process contributes to the high cost of treatment, creates manufacturing and logistical challenges and can leave patients waiting for treatment.
Arovella’s approach uses healthy donor-derived invariant natural killer T (iNKT) cells, manufactured in advance and not requiring a patient’s own cells. The company can produce multiple treatment doses and store them ready for use off the shelf. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.
| Feature | Conventional autologous CAR-T | Arovella’s approach |
|---|---|---|
| Cell source | Each patient’s own cells | Healthy donor-derived iNKT cells |
| Manufacturing timing | Made for each individual patient | Manufactured in advance of patient treatment |
| Patient wait | Can leave patients waiting for treatment | Potential to eliminate manufacturing-related delays |
| Storage | Not addressed in the announcement | Stored and ready for use off the shelf |
The company said this approach has the potential to eliminate manufacturing-related delays, simplify treatment logistics and broaden access for patients. These benefits have not yet been demonstrated in patients.
Dr Nicole van der Weerden, Acting CEO
“By manufacturing from healthy donor cells in advance, we are building a bank of off-the-shelf clinical material…”
Third batch and trial completion
A third batch, expected to be released by end December, is anticipated to provide sufficient material to complete the phase 1 trial of 46 patients. The announcement does not disclose manufacturing costs, yields or dose numbers.
The second release builds on the first clinical batch, which cleared regulatory standard and allowed The Alfred in Melbourne to be activated as the initial trial site.
Hospital sites expand access as dosing nears
Arovella is progressing activation of additional clinical trial sites. The Epworth Hospital in Melbourne has been activated, while St Vincent’s Hospital in Sydney and Mater Hospital in Brisbane are expected to be activated soon.
The company said these sites will broaden access for eligible patients and support recruitment and execution. Screening for eligible patients is under way.
According to the company, screening and the new sites mean it can expand the trial quickly once the first patient is dosed this month. Product and sites are both now positioned ahead of that milestone.
David Williams, Chairman
“We are ready to go and will soon have enough product on the shelf to dose all 46 patients supported by five exceptional hospital sites as we move towards dosing expected in late October.”
Dr van der Weerden described treating the first patient as “a defining milestone”, noting that “As patient screening quickens, we will have enough product on the shelf to treat the 46 patients.”
What’s next for Arovella
The announcement points to the following sequence of events:
- First patient dosing: this month, with dosing expected in late October
- Activation of St Vincent’s and Mater sites: expected “soon” (no date given)
- Third batch: expected to be released by end December
- Phase 1 trial: complete dosing of 46 patients
The company’s platform centres on ALA-101, which consists of CAR19-iNKT cells modified to produce a CAR that targets CD19, an antigen found on the surface of numerous cancer types. ALA-101 has had its Investigational New Drug application accepted by the US Food and Drug Administration (FDA), and the iNKT platform is licensed from Imperial College London.
Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group.
Investors exploring the pipeline beyond ALA-101 can read our deep-dive into Arovella’s CLDN18.2 preclinical data, which covers the serial tumour challenge results in pancreatic and gastric cell lines and the IL-12-TM armouring technology.
With a second batch released and sites being activated, the next catalysts are the first patient dosing, further site activations and the third batch release.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX news delivered to their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts the moment market-moving healthcare and biotech announcements break.